eligibility_summary
Eligible: ESCC ≥70 y, ECOG 0–1, RECIST-measurable lesion, stage II–IVB (IVB only supraclavicular/abdominal LN), expected survival ≥6 mo, fit for concurrent chemo‑RT±targeted, adequate organ function (marrow, liver, renal, LVEF≥50%), contraception as applicable. Exclude: EGFR mAb/TKI <6 mo, other trials <30 d, major comorbidity, active infection, symptomatic/unstable brain mets, fistula or major‑vessel invasion, allergy, ≥G2 neuropathy/hearing loss, pregnancy, substance/mental disorder.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06988956: Phase II, randomized, open-label trial in elderly patients with unresectable esophageal squamous cell carcinoma comparing concurrent chemoradiotherapy (radiotherapy + S‑1) with or without nimotuzumab. Interventions/mechanisms: Nimotuzumab—humanized IgG1 monoclonal antibody targeting EGFR (ErbB1), blocks ligand binding, inhibits downstream MAPK/ERK and PI3K/AKT signaling, and can trigger ADCC, enhances radiosensitization of EGFR‑expressing tumor cells. S‑1 (tegafur-based oral fluoropyrimidine, tegafur + modulators) generates 5‑FU, inhibiting thymidylate synthase and RNA/DNA synthesis, also radiosensitizer. Radiotherapy induces DNA double‑strand breaks. Targets/pathways: EGFR on ESCC cells, RAS–RAF–MEK–ERK and PI3K–AKT pathways, thymidylate synthase–mediated nucleotide synthesis, tumor DNA damage/repair, NK-cell mediated ADCC.